论文部分内容阅读
有关透析患者应用人类重组红细胞生成素(EPO)已有不少经验和评价,然而EPO对透析前患者的有效作用认识尚少,本文总结了后者应用EPO治疗的有关文献和经验。 EPO对贫血的作用业已证明EPO对肾功能不全尚无明显透析指征的患者有纠正贫血的作用,经EPO三种不同剂量与血球压积比较观察表明,用150u/kg、3次/周静注血球压积较之用50、100u/kg、3次/周静注增高更明显,而安慰剂组血球压积则无改变。经117例透析前患者应用EPO显示50u/kg、3次/周可使每周血球压积上升0.9%;100u/kg、3次/
There are a lot of experiences and comments on the application of human recombinant erythropoietin (EPO) in dialysis patients. However, there is little understanding on the effect of EPO on pre-dialysis patients. This article summarizes the literature and experience of the latter using EPO. The role of EPO on anemia It has been demonstrated that EPO has ameliorating effects on anemia in patients with renal insufficiency who have no significant indication for dialysis. Comparisons of the three different doses of EPO and hematocrit showed that patients with 150u / kg, 3 beats / week of statin The hematocrit was more pronounced than the 50, 100u / kg, 3 / week intravenous infusion, whereas the placebo group had no change in hematocrit. The application of EPO in 117 patients before dialysis showed that the weekly hematocrit increased by 0.9% with 50u / kg and 3 times / week; 100u / kg, 3 times /